Literature DB >> 8474686

Beta A4 protein deposition in familial Alzheimer's disease with the mutation in codon 717 of the beta A4 amyloid precursor protein gene and sporadic Alzheimer's disease.

N J Cairns1, A Chadwick, P L Lantos, R Levy, M N Rossor.   

Abstract

Beta A4 protein immunoreactivity in the neocortex and hippocampus of familial Alzheimer's disease (AD) including the case with the beta A4 amyloid precursor protein (APP) gene mutation in codon 717 (APP717 Val-->Ile) and sporadic cases of AD is described. A semi-automatic image analysis system was used to quantify beta A4 protein load in the isocortex of the frontal and temporal lobes and in subfields of the hippocampus. Immunoreactivity was measured in ten cases of sporadic AD and in five cases of familial AD including one in which the APP717 Val-->Ile mutation was present. Beta A4 protein load, as measured by square microns of immunoreactivity per square millimetre of cortex, was similar in the frontal and temporal isocortex in both sporadic and familial AD. There was greater variation in beta A4 protein load in subfields of the hippocampus but these differences were not significant between sporadic and familial cases. In the case with the APP717 Val-->Ile mutation. Beta A4 protein load in isocortex was greater than the mean for familial and sporadic cases of AD but less than the most severe cases of beta A4 protein deposition which were found in sporadic AD. In addition, the case with the APP717 Val-->Ile mutation has the same cytoskeletal pathology as sporadic cases of AD. The mechanism by which normal and mutant APP is processed to produce amyloidogenic fragments remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8474686     DOI: 10.1016/0304-3940(93)90755-a

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.

Authors:  Gregory Hook; Vivian Hook; Mark Kindy
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

2.  Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development.

Authors:  Avindra Nath; Elizabeth Hall; Marnia Tuzova; Michael Dobbs; Melina Jons; Caroline Anderson; Jerold Woodward; Zhihong Guo; Weiming Fu; Richard Kryscio; David Wekstein; Charles Smith; William R Markesbery; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

3.  Chromosome 14 familial Alzheimer's disease: the clinical and neuropathological characteristics of a family with a leucine-->serine (L250S) substitution at codon 250 of the presenilin 1 gene.

Authors:  R J Harvey; D Ellison; J Hardy; M Hutton; P K Roques; J Collinge; N C Fox; M N Rossor
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

4.  Transforming growth factor beta2 is a neuronal death-inducing ligand for amyloid-beta precursor protein.

Authors:  Yuichi Hashimoto; Tomohiro Chiba; Marina Yamada; Mikiro Nawa; Kohsuke Kanekura; Hiroaki Suzuki; Kenzo Terashita; Sadakazu Aiso; Ikuo Nishimoto; Masaaki Matsuoka
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

5.  Antibodies to presenilin proteins detect neurofibrillary tangles in Alzheimer's disease.

Authors:  G M Murphy; L S Forno; W G Ellis; D Nochlin; E Levy-Lahad; P Poorkaj; T D Bird; Z Jiang; B Cordell
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

6.  Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene.

Authors:  D M Mann; T Iwatsubo; Y Ihara; N J Cairns; P L Lantos; N Bogdanovic; L Lannfelt; B Winblad; M L Maat-Schieman; M N Rossor
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

7.  Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier - phenotypic variability in autosomal dominant Alzheimer's disease.

Authors:  Grace M Lloyd; Jorge A Trejo-Lopez; Yuxing Xia; Karen N McFarland; Sarah J Lincoln; Nilüfer Ertekin-Taner; Benoit I Giasson; Anthony T Yachnis; Stefan Prokop
Journal:  Acta Neuropathol Commun       Date:  2020-03-12       Impact factor: 7.801

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.